Key Takeaways
- • James Dacombe, 25, became Europe's youngest billionaire after his AI hardware startup Olix reached a $3.3 billion valuation, giving him a personal fortune of roughly $1 billion, according to the article.
- • Olix has raised $532 million from investors including Fundomo, chip designer Arm, and the U.K. government's Sovereign AI fund.
- • Dacombe received a Thiel Fellowship in 2022, a program launched in 2011 that offers a $250,000 grant to bright innovators aged 22 or younger who leave school to build companies.
- • Thiel's philanthropy extends beyond the fellowship into longevity biotech (Oisín Biotechnologies, Leucadia Therapeutics, X-Therma, Methuselah Foundation) and the Seasteading Institute.
- • Dacombe's earlier startup CoMind is running clinical trials at London's St Bartholomew's Hospital, with a projected commercial launch by 2027.
Summary
Olix is developing hyper-specialized AI chips for discrete tasks such as processing prompts or generating answers, in contrast to the general-purpose chips built by Nvidia. The company connects these chips with a custom optical network that uses infrared light rather than electrical signals, aiming to reduce the RC delay that limits copper wiring and to cut the power consumption of AI data infrastructure. Investors including Fundomo, Arm, and the U.K. government's Sovereign AI fund have committed a combined $532 million.
The Thiel Fellowship, launched in 2011, provides $250,000 to innovators aged 22 or younger who stop out of college or high school to build companies. The program imposes no commercial milestones, takes no equity, and requires only that fellows remain out of school. The article characterizes the fellowship as a form of venture philanthropy aimed at what Thiel views as a higher education bubble, and it notes that academia initially criticized the program. Previous fellows include Ethereum creator Vitalik Buterin and Austin Russell.
The article places Thiel's giving within a broader portfolio that includes longevity biotech, such as Oisín Biotechnologies, Leucadia Therapeutics, and X-Therma, as well as funding for the Methuselah Foundation and the Seasteading Institute. It also compares Thiel's approach with Schmidt Sciences and Emerson Collective. Dacombe's earlier venture, CoMind, is running clinical trials at St Bartholomew's Hospital in London using non-invasive lasers to measure brain blood flow and pressure in intensive care patients, with commercial launch projected for 2027.
The article also situates Dacombe within a wave of young AI founders, citing the Cursor founders, Fabian Hedin of Lovable, and the Mercor founders, though these figures are reported in the article rather than independently verified here.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.